Category Archives: Other

Guangzhou Medical Insurance Separate Payment Policy Targets Hypertension Outpatient Care

Guangzhou, Sept 1, 2026 — Guangzhou implemented an updated medical insurance separate payment policy, refining how nationally negotiated drugs are reimbursed for Category I outpatient-specific diseases such as hypertension while maintaining existing rules for general outpatient care and Category II disease clinics.

Policy Snapshot

AttributeDetail
Effective dateSept 1, 2026
LocationGuangzhou, Guangdong Province
Policy nameImproved Medical Insurance Separate Payment Management Policy
ScopeNationally negotiated drugs (including agreement-period and converted catalog drugs; bid-winning drugs)
Key changeCategory I outpatient-specific diseases (e.g., hypertension) now require a designated separate payment institution
UnchangedGeneral outpatient care and Category II outpatient-specific disease separate payment rules

How Separate Payment Works

Under the separate payment mechanism, costs for nationally negotiated drugs are not counted toward general outpatient or outpatient-specific disease benefit caps. Instead, the basic medical insurance pooled fund settles these costs separately with designated medical institutions, bypassing standard reimbursement limits.

Patient Access Pathways

  • Pathway 1 (General & Category II): Insured patients visiting their selected general outpatient institutions, specialized designated hospitals, or Category II outpatient-specific disease institutions can obtain separate payment drug prescriptions without changes to existing reimbursement rules.
  • Pathway 2 (Category I): Insured patients with Category I outpatient-specific disease benefits must select one designated separate payment institution for each condition. Prescriptions for separate payment drugs issued at the selected facility qualify for the separate payment benefit. Patients who fail to register a separate payment designation or visit non-selected institutions cannot access the separate payment benefit and must claim reimbursement under original Category I disease caps.

Hypertension Adjustment Example

Under the new rules, a hypertension patient previously able to obtain specialty drugs at both Hospital A and Hospital B must now designate only one facility as their hypertension separate payment institution. At the selected hospital, hypertension drugs qualify for separate payment—reimbursed at inpatient rates without counting toward the hypertension benefit cap. At non-selected hospitals, the same drugs are reimbursed at standard outpatient-specific disease rates and count toward the annual cap.

Market Impact Analysis

The policy tightens patient routing controls for high-cost nationally negotiated drugs used in chronic disease management, steering hypertension and other Category I patients toward single-institution loyalty. By requiring a designated separate payment facility, regulators are creating a closed-loop system that simplifies fund settlement for insurers while concentrating prescription volume at selected hospitals.

For pharmaceutical manufacturers, the change means drug uptake for hypertension therapies on the national negotiation list will increasingly depend on whether hospitals secure separate payment designation status and successfully attract patient registrations. Hospitals with strong primary care networks and chronic disease management programs are positioned to capture patient volume, while smaller facilities may see negotiated drug prescriptions migrate to competitors.

The inpatient-level reimbursement rate for separate payment drugs removes the financial ceiling that previously constrained long-term hypertension therapy adherence, potentially improving patient persistence on premium antihypertensive agents. However, the single-institution restriction limits patient choice and may reduce competitive pricing pressure between hospitals for chronic disease drug dispensing.

Forward-Looking Statement

Healthcare analysts expect Guangzhou’s separate payment model to be monitored closely by other tier-one cities as a template for managing nationally negotiated drug costs within outpatient chronic disease frameworks. If the single-institution designation proves effective in controlling fund leakage and improving settlement efficiency, similar restrictions could roll out across the Pearl River Delta by mid-2027. Pharmaceutical companies with hypertension and diabetes assets on the national negotiation list should prioritize partnerships with hospitals likely to secure high patient registration volumes under the new designation system.-China Health Reform Pulse

Policy Source: https://www.gd.gov.cn/zwgk/zdlyxxgkzl/ylws/content/post_4950117.html

Shanghai Opens TCM Procurement Alliance Listing for Fourth Batch

Shanghai, Aug 31, 2026 — Shanghai’s Medical Procurement Center opened the online application channel for the fourth batch and second-batch renewal of the National Traditional Chinese Medicine Patent Medicines and Simple Preparations Purchasing Alliance centralized procurement, requiring selected manufacturers to complete platform registration by Sept 15, 2026.

Policy Snapshot

AttributeDetail
IssuerShanghai Medical Centralized Bidding and Procurement Affairs Management Center
DocumentNotice on Launching Application and Networking for Fourth and Second Batch Renewal of National TCM Patent Medicines Purchasing Alliance
BatchesZCYLM-2026-1 (Fourth Batch); ZCYLM-2026-2 (Second Batch Renewal)
Application windowAug 31, 2026 – Sept 15, 2026
PlatformShanghai Medical Procurement Association portal (www.smpaa.cn)
ModuleBusiness Operations → My Drug Library
Listing typeNon-national centralized procurement related drugs
Sub-typeNational alliance centralized procurement, renewal drugs (selected channel)

Key Provisions

  • Mandatory filing — All drugs on Shanghai’s supply list for the two batches must be registered; previously listed selected drugs are exempt from re-application.
  • Digital workflow — Enterprises log into the procurement subsystem via the SMPAA portal, navigate to the drug library module, and select the designated listing categories to submit product information.
  • Supply lists — Two annexes detail the selected varieties: the fourth batch (ZCYLM-2026-1) and the second-batch renewal (ZCYLM-2026-2).

Market Impact Analysis

The 16-day application window creates a tight compliance timeline for TCM manufacturers seeking to maintain Shanghai market access under the national alliance procurement framework. By routing the fourth batch and renewal products through a dedicated “selected channel” within the non-national centralized procurement category, regulators are preserving the distinction between national volume-based procurement and alliance-level TCM procurement while streamlining the local listing process.

For pharmaceutical companies, failure to register by the Sept 15 deadline risks exclusion from Shanghai’s public hospital and community health center formularies, a significant volume channel in one of China’s wealthiest healthcare markets. The exemption for already-listed products reduces administrative duplication but requires manufacturers to verify their current platform status against the new supply lists.

Forward-Looking Statement

Industry analysts expect Shanghai’s listing template to be replicated across other alliance member provinces in September, as the national TCM procurement alliance synchronizes local platform onboarding ahead of the fourth-quarter procurement cycle. The second-batch renewal mechanism suggests the alliance is transitioning toward a rolling contract model for mature TCM products, potentially reducing annual re-tendering friction. Companies with selected TCM formulations should prioritize the Shanghai digital registration workflow, as delays in the initial listing phase could cascade into missed procurement windows across the alliance network. Final supply list confirmations are anticipated by late September 2026.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/31/24240.shtml

Shanghai Opens TCM Procurement Alliance Listing for Fourth Batch

Shanghai, Aug 31, 2026 — Shanghai’s Medical Procurement Center opened the online application channel for the fourth batch and second-batch renewal of the National Traditional Chinese Medicine Patent Medicines and Simple Preparations Purchasing Alliance centralized procurement, requiring selected manufacturers to complete platform registration by Sept 15, 2026.

Policy Snapshot

AttributeDetail
IssuerShanghai Medical Centralized Bidding and Procurement Affairs Management Center
DocumentNotice on Launching Application and Networking for Fourth and Second Batch Renewal of National TCM Patent Medicines Purchasing Alliance
BatchesZCYLM-2026-1 (Fourth Batch); ZCYLM-2026-2 (Second Batch Renewal)
Application windowAug 31, 2026 – Sept 15, 2026
PlatformShanghai Medical Procurement Association portal (www.smpaa.cn)
ModuleBusiness Operations → My Drug Library
Listing typeNon-national centralized procurement related drugs
Sub-typeNational alliance centralized procurement, renewal drugs (selected channel)

Key Provisions

  • Mandatory filing — All drugs on Shanghai’s supply list for the two batches must be registered; previously listed selected drugs are exempt from re-application.
  • Digital workflow — Enterprises log into the procurement subsystem via the SMPAA portal, navigate to the drug library module, and select the designated listing categories to submit product information.
  • Supply lists — Two annexes detail the selected varieties: the fourth batch (ZCYLM-2026-1) and the second-batch renewal (ZCYLM-2026-2).

Market Impact Analysis

The 16-day application window creates a tight compliance timeline for TCM manufacturers seeking to maintain Shanghai market access under the national alliance procurement framework. By routing the fourth batch and renewal products through a dedicated “selected channel” within the non-national centralized procurement category, regulators are preserving the distinction between national volume-based procurement and alliance-level TCM procurement while streamlining the local listing process.

For pharmaceutical companies, failure to register by the Sept 15 deadline risks exclusion from Shanghai’s public hospital and community health center formularies, a significant volume channel in one of China’s wealthiest healthcare markets. The exemption for already-listed products reduces administrative duplication but requires manufacturers to verify their current platform status against the new supply lists.

Forward-Looking Statement

Industry analysts expect Shanghai’s listing template to be replicated across other alliance member provinces in September, as the national TCM procurement alliance synchronizes local platform onboarding ahead of the fourth-quarter procurement cycle. The second-batch renewal mechanism suggests the alliance is transitioning toward a rolling contract model for mature TCM products, potentially reducing annual re-tendering friction. Companies with selected TCM formulations should prioritize the Shanghai digital registration workflow, as delays in the initial listing phase could cascade into missed procurement windows across the alliance network. Final supply list confirmations are anticipated by late September 2026.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/31/24240.shtml